An Australian research team investigated evidence which links the gut microbiome with specific psychiatric disorders and age-related cognitive impairment.
The human body is host to a vast number of diverse microbes that perform important and beneficial functions. Evidence is now emerging that communication between the gastrointestinal tract and the central nervous system is both bidirectional and influenced, in part, by the gut microbiome.
4D pharma plc (LON:DDDD) is a pharmaceutical company focused on developing therapeutics from the human gut microbiome. 4D is a world leader in the development of live biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism (such as a bacteria) that is applicable to the prevention, treatment or cure of a disease.